Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema once‑weekly in participants with overweight or obesity
2023-509273-24-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide and semaglutide in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoints: Relative change in body weight and Achievement of ≥5% weight reduction. Started Jun 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2023-509273-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509273-24-00.